Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. Although most patients with advanced GISTs benefit from imatinib mesylate (IM) as standard targeted therapy, the optimal duration of adjuvant IM for GIST patients with high risk of recurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Toshihisa, Togawa, Tamotsu, Onishi, Kenji, Iida, Atsushi, Sato, Yasunori, Goi, Takanori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691891/
https://www.ncbi.nlm.nih.gov/pubmed/33228387
http://dx.doi.org/10.1177/2324709620970736

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691891/
https://www.ncbi.nlm.nih.gov/pubmed/33228387
http://dx.doi.org/10.1177/2324709620970736

Ejemplares similares